risperidone has been researched along with Bilateral Headache in 10 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this multicenter, double-blind, 16-week, placebo-controlled study conducted at 43 American sites from July 2006 to October 2007, patients with chronic, stable schizophrenia or schizoaffective disorder diagnosed with DSM-IV-TR were randomly assigned to receive aripiprazole (2-15 mg/d) or placebo in addition to a stable regimen of quetiapine (400-800 mg/d) or risperidone (4-8 mg/d)." | 9.14 | A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. ( Assunção-Talbott, S; Carson, WH; Correll, CU; Goff, DC; Kane, JM; Kirkpatrick, B; Marder, SR; Pikalov, A; Sun, W; Vester-Blokland, E, 2009) |
| "The safety and efficacy of the first long-acting injectable atypical antipsychotic, risperidone, were assessed in stable patients with schizophrenia switched from oral antipsychotic medications." | 9.11 | Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. ( Berry, SA; Eerdekens, E; Eerdekens, M; Lindenmayer, JP, 2004) |
| "In this multicenter, double-blind, 16-week, placebo-controlled study conducted at 43 American sites from July 2006 to October 2007, patients with chronic, stable schizophrenia or schizoaffective disorder diagnosed with DSM-IV-TR were randomly assigned to receive aripiprazole (2-15 mg/d) or placebo in addition to a stable regimen of quetiapine (400-800 mg/d) or risperidone (4-8 mg/d)." | 5.14 | A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. ( Assunção-Talbott, S; Carson, WH; Correll, CU; Goff, DC; Kane, JM; Kirkpatrick, B; Marder, SR; Pikalov, A; Sun, W; Vester-Blokland, E, 2009) |
| "The safety and efficacy of the first long-acting injectable atypical antipsychotic, risperidone, were assessed in stable patients with schizophrenia switched from oral antipsychotic medications." | 5.11 | Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. ( Berry, SA; Eerdekens, E; Eerdekens, M; Lindenmayer, JP, 2004) |
| "A 17-year-old girl gained more than 25 kg in weight during treatment with risperidone and subsequently developed headache, diplopia and loss of vision due to IIH." | 3.81 | [Idiopathic intracranial hypertension and obesity]. ( Braakman, HM; Naarden, MT; Porro, GL; Schuitemaker, A; Straver, JS; van Doormaal, TP, 2015) |
| " There was a clear relationship between the number of active alleles and the pharmacokinetic parameters for risperidone and 9-hydroxyrisperidone, but there were no differences for total active moiety." | 2.75 | Effects of CYP2D6 genotype on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers. ( Abad-Santos, F; Gallego-Sandín, S; López-Rodríguez, R; Novalbos, J; Ochoa, D; Román, M, 2010) |
| "Risperidone was measured in plasma using high performance liquid chromatography with ultraviolet detection." | 2.73 | Rifampin, a cytochrome P450 3A inducer, decreases plasma concentrations of antipsychotic risperidone in healthy volunteers. ( Mahatthanatrakul, W; Nontaput, T; Ridtitid, W; Sunbhanich, M; Wongnawa, M, 2007) |
| "Olanzapine-treated patients had greater HAM-D-21 (p = ." | 2.72 | Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial. ( Baker, RW; Brown, EB; Jamal, HH; Perlis, RH; Schuh, LM; Tohen, M; Zarate, CA, 2006) |
| "Risperidone was well tolerated, and patients treated with risperidone demonstrated significantly greater improvement at endpoint on the ABC than those who received placebo [-27." | 2.71 | Short- and long-term efficacy and safety of risperidone in adults with disruptive behavior disorders. ( Eerdekens, M; Gagiano, C; Read, S; Thorpe, L; Van Hove, I, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (80.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Naarden, MT | 1 |
| Schuitemaker, A | 1 |
| Braakman, HM | 1 |
| van Doormaal, TP | 1 |
| Porro, GL | 1 |
| Straver, JS | 1 |
| Findling, RL | 1 |
| Kane, JM | 1 |
| Correll, CU | 1 |
| Goff, DC | 1 |
| Kirkpatrick, B | 1 |
| Marder, SR | 1 |
| Vester-Blokland, E | 1 |
| Sun, W | 1 |
| Carson, WH | 1 |
| Pikalov, A | 1 |
| Assunção-Talbott, S | 1 |
| Novalbos, J | 1 |
| López-Rodríguez, R | 1 |
| Román, M | 1 |
| Gallego-Sandín, S | 1 |
| Ochoa, D | 1 |
| Abad-Santos, F | 1 |
| Lindenmayer, JP | 1 |
| Eerdekens, E | 1 |
| Berry, SA | 1 |
| Eerdekens, M | 2 |
| Listernick, R | 1 |
| Gagiano, C | 1 |
| Read, S | 1 |
| Thorpe, L | 1 |
| Van Hove, I | 1 |
| Perlis, RH | 1 |
| Baker, RW | 1 |
| Zarate, CA | 1 |
| Brown, EB | 1 |
| Schuh, LM | 1 |
| Jamal, HH | 1 |
| Tohen, M | 1 |
| Mahatthanatrakul, W | 1 |
| Nontaput, T | 1 |
| Ridtitid, W | 1 |
| Wongnawa, M | 1 |
| Sunbhanich, M | 1 |
| Bahk, WM | 1 |
| Pae, CU | 1 |
| Chae, JH | 1 |
| Jun, TY | 1 |
| Kim, KS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-blind, Placebo-controlled, 16 Week Study of Aripiprazole Used as Dual Therapy in the Treatment of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder Demonstrating an Inadequate Response to Quetiapine o[NCT00325689] | Phase 4 | 323 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| Open-Label Trial Exploring A Switching Regimen From Oral Neuroleptics, Other Than Risperidone, To Risperidone Depot Microspheres[NCT00034775] | Phase 3 | 141 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for risperidone and Bilateral Headache
| Article | Year |
|---|---|
Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; | 2008 |
6 trials available for risperidone and Bilateral Headache
| Article | Year |
|---|---|
A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Aripiprazole; Diagnostic and Statistical Manual of Men | 2009 |
Effects of CYP2D6 genotype on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers.
Topics: Adult; Alleles; Cross-Over Studies; Cytochrome P-450 CYP2D6; Dizziness; Female; Genetic Variation; G | 2010 |
Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Diarrhea; Drug Administration Schedule; Dr | 2004 |
Short- and long-term efficacy and safety of risperidone in adults with disruptive behavior disorders.
Topics: Adolescent; Adult; Attention Deficit and Disruptive Behavior Disorders; Disorders of Excessive Somno | 2005 |
Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial.
Topics: Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Appetite; Benzodiazepines; Bipolar Disor | 2006 |
Rifampin, a cytochrome P450 3A inducer, decreases plasma concentrations of antipsychotic risperidone in healthy volunteers.
Topics: Administration, Oral; Adult; Antibiotics, Antitubercular; Antipsychotic Agents; Area Under Curve; Ca | 2007 |
3 other studies available for risperidone and Bilateral Headache
| Article | Year |
|---|---|
[Idiopathic intracranial hypertension and obesity].
Topics: Adolescent; Antipsychotic Agents; Female; Headache; Humans; Obesity; Pseudotumor Cerebri; Risperidon | 2015 |
A 17-year-old boy previously diagnosed with chronic Lyme disease. Patient complained of low-grade fevers, headaches, pharyngitis, and suspected his mother was trying to poison him.
Topics: Adolescent; Antipsychotic Agents; Chronic Disease; Diagnosis, Differential; Headache; Humans; Lyme D | 2004 |
A case of brief psychosis associated with an arachnoid cyst.
Topics: Antipsychotic Agents; Arachnoid Cysts; Hallucinations; Headache; Humans; Magnetic Resonance Imaging; | 2002 |